 I. To compare the event-free survival EFS of patients with intermediate-risk IR rhabdomyosarcoma RMS treated with surgery, radiotherapy, and vincristine vincristine sulfate, dactinomycin, and cyclophosphamide VAC alternating with vincristine and irinotecan irinotecan hydrochloride VI VACVI to that of patients treated with surgery, radiotherapy and VACVI plus temsirolimus. 